Fig. 2

Commercially available drugs attenuate lethal TBI-induced hematopoietic reduction. Mice were intraperitoneally administered the clinical dosage (10 μg/kg of body weight/day) of G-CSF once-daily for 4 times and RP once a week for 3 times (GRP #4) starting within 2 h after exposure to a 7.25-Gy dose of TBI. Mice treated with TBI only received injections of the normal saline solution as vehicle. “7.25 Gy + GRP” and “7.25 Gy” indicate the results of TBI mice with and without GRP #4, respectively. a Mitigative effects of GRP #4 administered immediately post-TBI are represented in a Kaplan-Meier survival curve until day 21 (n = 5 in each group). Statistically significant difference was evaluated by the log-rank test compared with TBI only (P < 0.05). b Body weight changes in the surviving mice (n = 5 in each group). c Representative photographs of splenic endogenous colonies on day 21 are shown. Scale bars, 1 cm. d Splenic weights and total viable cell numbers in the e spleen and f bone marrow observed in the TBI and control mice treated with or without GRP #4 (n = 5 per group). The data are expressed as the means ± SD. Statistically significant differences were evaluated by one-way ANOVA and the multiple comparison tests (**P < 0.01, *P < 0.05)